#46
|
||||
|
||||
Äëÿ ïèðàöåòàìà 4,8 â ñóòêè ïîêàçàí åãî àíòèàããðåãàöèîííûé ýôôåêò è äàæå åñòü íåáîëüøîå èññëåäîâàíèå äëÿ ïðîôèëàêòèêè ïîâòîðíîãî èíñóëüòà ïðîòèâ 600 ìã àñïèðèíà:
Evers S, Grotemeyer KH. Piracetam and platelets--a review of laboratory and clinical data. Pharmacopsychiatry. 1999 Mar;32 Suppl 1:44-8. Stockmans F, Deberdt W, Nystrom A, Nystrom E, Stassen JM, Vermylen J, Deckmyn H. Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb Haemost. 1998 Jan;79(1):222-7. Grotemeyer KH, Evers S, Fischer M, Husstedt IW. Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. J Neurol Sci. 2000 Dec 1;181(1-2):65-72.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#47
|
||||
|
||||
Ïîëüçóÿñü ñëó÷àåì, õîòåëîñü áû ñïðîñèòü, ÷òî Âû äóìàåòå ïî ïîâîäó âîò ýòîãî?
British National Formulary 52 (ýòî - îòêóäà, ñîáñòâåííî, âçÿòî) Ïðèâîæó òîëüêî ïîêàçàíèÿ è äîçû. PIRACETAM Indications: adjunctive treatment of cortical myoclonus Dose: Initially 7.2 g daily in 2–3 divided doses, increased according to response by 4.8 g daily every 3–4 days to max. 20 g daily (subsequently, attempts should be made to reduce dose of concurrent therapy); child under 16 years not recommended Ýòî ÅÄÈÍÑÒÂÅÍÍÎÅ ëèöåíçèðîâàííîå ïîêàçàíèå äëÿ ïðèìåíåíèÿ ïèðàöåòàìà â Áðèòàíèè. Ñ ýòèì êîãäà ñòîëêíóëàñü òóò, òî ïîñëå ðàáîòû â ðîäíîé ïîñòñîâåòñêîé Óêðàèíå áûëà íåñêîëüêî ðàñòåðÿíà. Èëè ÿ ÷òî-òî íå òàê ïîíÿëà, êîëëåãè? |
#48
|
||||
|
||||
Öèòàòà:
|
#49
|
||||
|
||||
Öèòàòà:
|
#50
|
||||
|
||||
Âñå âåðíî: î÷åíü ìîæåò áûòü, ÷òî åùå çàâèñèò îò çàðåãèñòðèðîâàííûõ ïîêàçàíèé â äàííîé ñòðàíå. Íåêîòîðûå ïóáëèêàöèè:
Epileptic Disord. 2000 Jun;2(2):99-105. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Genton P, Van Vleymen B. Centre Saint-Paul, Marseille, France. Piracetam (PIR) and levetiracetam (LEV), an S-enantiomer, are pyrrolidone derivatives that share similar chemical structures but have distinct pharmacological profiles and consequently different clinical uses. Although the mode of action of neither drug has been fully elucidated, they do not interact with inhibitory or excitatory neurotransmission or alter membrane excitability. A brain-specific stereoselective binding site has been identified for which LEV and other S-enantiomers, but not PIR, have high affinity. In preclinical studies, PIR significantly improves learning and memory; in contrast, LEV has less effect but is much more active in preventing seizures. Both drugs have a high therapeutic index and are well tolerated. PIR, a nootropic drug, is used in the therapy of age-related cognitive disturbances and poststroke aphasia. Clinical experience has also shown that at high doses it is effective against cortical myoclonus. LEV is an antiepileptic drug. Clinical trials have confirmed its efficacy in partial seizures and preliminary findings suggest that it is also effective in generalized seizures and myoclonus. ------------------------------------------ CNS Drug Rev. 2005 Summer;11(2):169-82. Piracetam: a review of pharmacological properties and clinical uses.Winblad B. Karolinska Institutet, Neurotec, Huddinge, University Hospital B 84, S-14186 Stockholm, Sweden. Piracetam, a derivative of the neurotransmitter gamma-aminobutyric acid (GABA), has a variety of physiological effects that may result, at least in part, from the restoration of cell membrane fluidity. At a neuronal level, piracetam modulates neurotransmission in a range of transmitter systems (including cholinergic and glutamatergic), has neuroprotective and anticonvulsant properties, and improves neuroplasticity. At a vascular level, it appears to reduce erythrocyte adhesion to vascular endothelium, hinder vasospasm, and facilitate microcirculation. This diverse range of physiological effects is consistent with its use in a range of clinical indications. Its efficacy is documented in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia. While high doses are sometimes necessary, piracetam is well tolerated. À â Øòàòàõ îí âîîáùå íå çàðåãèñòðèðîâàí...
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#51
|
||||
|
||||
... òàê êòî òàì ó êîãî äóáèíêó óêðàë?
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |